1E
11.1.2022 14:12:14 CET | Business Wire | Press release
1E , the leader in Digital Employee Experience (DEX), today appointed six new senior leaders in response to booming growth in the DEX category as organizations increasingly prioritize supporting the hybrid and remote work needs of employees.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220111005732/en/
“2022 is going to be an epic year for 1E. We start the year on the heels of our biggest quarter ever and the launch of the latest generation of our SaaS Digital Employee Experience platform, 1E Tachyon. We've also seen significant tailwinds as DEX has become a major boardroom priority as a way to understand employee engagement, happiness and productivity in uncertain times” said Mark Banfield, CEO of 1E. “These new appointments, half of whom are women, are a key piece of the puzzle in our aggressive growth strategy and will propel us to new heights as we lead the way in writing DEX history.”
Building an organization acutely focused on customer success was paramount to 1E’s business transformation. This new approach puts 1E customers at the center so that they are better equipped to support and improve the digital experience of their employees. 1E is also doubling down on product and technology. These new additions are reflective of this strategy.
New appointments include:
● Marie Palmer, Chief Customer Officer
● Ian Van Reenen, Chief Technology Officer
● Amy Collins, Senior Vice President, Product
● Alice Carlisle, Vice President, Sales for EMEA
● Lucas Ryder, Vice President, Sales for North America
● Jason Keogh, Field CTO
Marie Palmer joins as 1E’s Chief Customer Officer. Marie, who has over fifteen years of experience leading customer success teams, the last six of which were devoted to leading customer success for VMWare in EMEA and APAC.
Ian Van Reenen joins 1E as Chief Technology Officer. Ian, a veteran technologist, has over 20 years’ experience building products to help IT departments offer a more secure, efficient, and better service at companies such as Datto, Autotask and CentraStage.
Amy Collins has been promoted to Senior Vice President, Product. Amy has worked in the technology sector for 20 years and has spent most of this time in product roles building software products in fast growth, disruptive technology companies such as Brandwatch and Signal AI.
Alice Carlisle and Lucas Ryder join as Vice President of Sales for EMEA and North America respectively. Carlisle joins most recently from LogicMonitor, where she achieved significant growth in EMEA sales, and Ryder joins from Darktrace, where he ran sales in North America. Both worked together previously at Autotask and Datto.
Jason Keogh has been promoted to Field CTO to help 1E customers map their DEX requirements back to technology solutions and to build a feedback loop between the customer base and product team. Prior to joining 1E, Jason was founder and CTO of iQuate.
About 1E
1E are the innovators in Digital Employee Experience (DEX) that supports the work from anywhere enterprise, so employees are secure, supported, and productive wherever they want to be. The 1E Tachyon Platform provides real-time diagnosis, remediation and automation that fixes issues, fast and without interruption. It puts employees in control, through self-service, self-heal and sentiment monitoring to understand how they really feel and reduces help desk calls and ultimately costs. That’s why more than 500 organizations in 42 countries trust 1E to help them manage 11 million endpoints seamlessly. For more information, visit www.1E.com .
###
View source version on businesswire.com: https://www.businesswire.com/news/home/20220111005732/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 09:00:00 CEST | Press release
News summary: TOHKnet is exploring next-generation PON to meet enterprise demand while maintaining continuity across its regional fiber network Using Adtran technology, the trial validated 50G PON, XGS-PON and EPON operating together on a single fiber network Results show a practical path to evolve networks, enabling phased upgrades while maximizing fiber assets and avoiding service disruption Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network
Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 09:00:00 CEST | Press release
Study to evaluate rupitasertib, Evexta Bio’s first-in-class oral dual-node, S6K and AKT1/3 inhibitor in combination with giredestrant in second-line ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer; expected to initiate in Q4 2026First clinical collaboration and supply agreement for Evexta Bio with rupitasertib and for Roche with giredestrant; results to inform future strategy for rupitasertib combination in ER+ HER2- advanced /metastatic breast cancer Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib
Bending Spoons has entered into a definitive agreement to acquire Airtable for $1.285 billion4.8.2026 08:30:00 CEST | Press release
Bending Spoons S.p.A. (NASDAQ: BSP) announced that it has entered into a definitive agreement to acquire Airtable, in an all-cash transaction that values Airtable at an enterprise value of $1.285 billion, which, together with Airtable’s current net cash-and-cash-equivalents balance, implies an equity value of approximately $2.25 billion. The acquisition is subject to customary closing conditions and approvals, including regulatory approvals. “We’re looking forward to welcoming Airtable into Bending Spoons,” said Luca Ferrari, Bending Spoons CEO and co-founder. “Airtable is a pioneering brand reshaping how teams organize data and manage critical workflows. The value being delivered is reflected in annual recurring revenue growing over 20% YoY to approximately $480 million as of June 2026, and joining forces with Bending Spoons will accelerate innovation even further. We’re committed to investing in Airtable for the long run, and doubling down on its core strength: bringing teams and wor
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
